Birchview Capital, LP Nektar Therapeutics Transaction History

Birchview Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$0.53 - $1.03 $47,700 - $92,700	-90,000 Reduced 76.27%	28,000 $16,000
Q4 2022 Feb 03, 2023	SELL	$2.03 - $4.28 $20,299 - $42,800	-10,000 Reduced 7.81%	118,000 $267,000
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $116,480 - $384,160	28,000 Added 28.0%	128,000 $690,000
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $303,240 - $515,480	28,000 Added 38.89%	100,000 $1.35 Million
Q2 2021 Aug 10, 2021	SELL	$16.52 - $20.4 $330,400 - $408,000	-20,000 Reduced 21.74%	72,000 $1.24 Million
Q1 2021 May 14, 2021	BUY	$16.56 - $25.46 $1.52 Million - $2.34 Million	92,000 New	92,000 $1.84 Million
Q3 2019 Nov 12, 2019	SELL	$16.91 - $36.27 $160,645 - $344,565	-9,500 Closed	0 $0
Q2 2018 Aug 02, 2018	BUY	$46.25 - $104.45 $439,375 - $992,275	9,500 New	9,500 $464,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Birchview Capital, LP with notifications on news.